Charles Wells

Charles Wells currently serves as Head of Therapeutics Development at the Gates Medical Research Institute in Cambridge, Massachusetts, where he joined in 2019. Previously, he served as Executive VP for Global Health and Development for Infectious Diseases at Evotec and Associate VP for Infectious Diseases Therapeutics at Sanofi during 2015-2019.

In this role he oversaw development activities for new therapeutic agents for malaria, bacterial diseases and biologics development for HIV and other viral infections. Prior to joining Sanofi in 2015, he served as Senior Medical Director for the development and initial registration of delamanid (DeltybaÒ) for treatment of multidrug resistant-tuberculosis at Otsuka Pharmaceuticals, during 2007-2015. Before Otsuka, he served as Chief of the International Research and Programs Branch of the Division of Tuberculosis Elimination at the U.S. Center for Disease Control and Prevention (CDC) during 2000-2007.

He is a native of North Carolina where he completed his medical studies at the University of North Carolina at Chapel Hill in 1992 and then his post-graduate medical training in internal medicine and infectious diseases at Emory University in 1998, as well as the Epidemic Intelligence Service at CDC.